更新于：2024-12-26
Promethazine Hydrochloride
盐酸异丙嗪
更新于：2024-12-26
概要
基本信息
简介盐酸异丙嗪，也被称为PHENERGAN®，是一种H1受体拮抗剂的药物。它于1951年首次被Wyeth制药公司在美国批准上市。盐酸异丙嗪可用于多种适应症，包括全年性和季节性过敏性鼻炎、血管运动性鼻炎和过敏性结膜炎。它也用于治疗轻度、不复杂的过敏性皮肤病变、改善对血液或血浆的过敏反应，并控制皮肤划痕反应。此外，在急性症状得到控制后，盐酸异丙嗪也可用作肾上腺素和其他标准措施的辅助治疗过敏性反应。该药还有效用于术前、术后或产科镇静，预防和控制与麻醉和手术相关的恶心和呕吐，并作为术后疼痛的辅助治疗。盐酸异丙嗪用于儿童和成人的镇静，以及运动病的积极和预防性治疗以及术后患者的止吐治疗。 |
药物类型 小分子化药 |
别名 (2-dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine、10-(2-Dimethylaminopropyl)phenothiazine、10-[2-(dimethylamino)propyl]phenothiazine + [20] |
作用机制 H1 receptor拮抗剂(组胺H1受体拮抗剂) |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C17H21ClN2S |
InChIKeyXXPDBLUZJRXNNZ-UHFFFAOYSA-N |
CAS号58-33-3 |
关联
68
项与 盐酸异丙嗪 相关的临床试验The Safety and effiCacy of HIbernation-Like Therapy Combining recanaLization in Ischemic Stroke: a Phase 1, Dose-escalation Study
Comparison of the effect of promethazine and topical magnesium sulfate on labor pain severity and progression in primiparous women
Observation of Oxaliplatin Hypersensitivity and Neurotoxicity in GI Tract, and Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors: A Prospective, Open-Label, Multicenter, Phase II Study
100 项与 盐酸异丙嗪 相关的临床结果
登录后查看更多信息
100 项与 盐酸异丙嗪 相关的转化医学
登录后查看更多信息
100 项与 盐酸异丙嗪 相关的专利（医药）
登录后查看更多信息
2,913
项与 盐酸异丙嗪 相关的文献（医药）2025-01-01JAAPA-Journal of the American Academy of Physician Assistants
Injectable promethazine in clinics and hospitals
Article
作者: Czech, Eric ; Overholser, Andrew ; Sizemore, Megan
ABSTRACT:
The Institute for Safe Medication Practices and the American Society of Health-System Pharmacists have advocated for removing all injectable promethazine from inpatient and outpatient settings; however, this drug is still being used despite the risk for tissue necrosis, gangrene, and possible amputation when it inadvertently is given by the subcutaneous or intra-arterial route. This article describes alternative injectable medications that can be selected based on patient comorbidities, indications, and clinician experience.
2024-12-06MEDICINE
To explore the protective mechanism of promethazine against hippocampal neuron injury based on network pharmacology and experimental verification
Article
作者: Bai, Li ; Li, Fang
This study aims to investigate the effect of promethazine (PMZ) on hippocampal neuronal injury through network pharmacology and in vivo experiments. Network pharmacology: The intersection genes of PMZ and Alzheimer Disease (AD) were obtained, and the core genes of PMZ in AD were screened. The intersection genes were enriched by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. In the in vitro experiment, mouse hippocampal neurons (HT22) were divided into control, glutamate (GLU) model, and GLU + PMZ treatment groups. The control group was given a complete culture medium, the model group was given GLU for 24 hours, the treatment group was given PMZ pretreatment for 3 hours, and then GLU was administered for 24 hours. Cell viability was determined, cell morphology was observed by microscopy, reactive oxygen species levels and glutathione content were detected, and protein expression of P53, PTGS2, SLC7A11, and GPX4 was detected by western blotting. Network pharmacology: A total of 317 PMZ targets, 1934 AD genes, 125 intersection genes, and 18 core genes, including P53 and PTGS2. Gene Ontology enrichment analysis showed that the effect of PMZ on AD was mainly related to cell proliferation, inflammation, hypoxia, synaptic structure, plasma membrane, and oxidoreductase activity. Kyoto Encyclopedia of Genes and Genomes results showed neuroactive ligand–receptor interaction, cell senescence, cancer pathway, PI3K-AKT signal pathway, neurodegeneration, and HIF-1 signal pathway. In vitro experiments: PMZ improved the GLU-induced decrease in cell viability and morphological changes in hippocampal neurons. PMZ inhibited reactive oxygen species levels and increased glutathione content in injured hippocampal neurons. Up-regulated of P53, SLC7A11 and GPX4 expression, and inhibited expression of PTGS2. PMZ regulates the SLC7A11–GPX4 antioxidant system to protect hippocampal neurons from oxidative stress injury.
2024-12-01Journal of PeriAnesthesia Nursing
Pharmacological Strategies for Postdischarge Nausea and Vomiting: Evidence-based Review Update
Review
作者: Kane, Terri D ; Tubog, Tito D
PURPOSE:
Evaluate the effectiveness of various drugs in preventing postdischarge nausea and vomiting (PDNV).
DESIGN:
Systematic review.
METHODS:
A search for evidence was conducted in PubMed, CINAHL, Cochrane Collaboration, and Google Scholar and gray literature. Only randomized controlled trials examining a pharmacological agent to prevent PDNV were included in the study. The quality appraisal of the literature was conducted using the proposed algorithm described in the Johns Hopkins Nursing Evidence-Based Practice Evidence Level and Quality Guide.
FINDINGS:
A total of 8 randomized controlled trials involving 1,441 patients were analyzed. The efficacy of pharmacological agents, including dexamethasone, olanzapine, ondansetron, palonosetron, ramosetron, promethazine, and casopitant in the prevention of PDNV, varied. Additionally, a combination of two or more drugs is a more effective therapy than using a single drug in mitigating PDNV. The review also underscored the individual patient factors that can play a significant role in identifying appropriate prevention and treatment modalities.
CONCLUSIONS:
There is limited evidence on the efficacy of pharmacological agents in preventing PDNV. The scarcity of large-scale, clinical trials specifically focusing on PDNV restricts the ability to recommend prophylactic drug therapy for reducing its incidence.
100 项与 盐酸异丙嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 感染 | 中国 | 1981-01-01 | |
| 疼痛 | 中国 | 1981-01-01 | |
| 麻醉 | 日本 | 1956-03-01 | |
| 过敏 | 美国 | 1952-04-11 | |
| 血管性水肿 | 美国 | 1952-04-11 | |
| 变应性结膜炎 | 美国 | 1952-04-11 | |
| 晕动病 | 美国 | 1952-04-11 | |
| 术后疼痛 | 美国 | 1952-04-11 | |
| 术后恶心呕吐 | 美国 | 1952-04-11 | |
| 过敏性鼻炎 | 美国 | 1952-04-11 | |
| 血管舒缩性鼻炎 | 美国 | 1952-04-11 | |
| 镇静 | 美国 | 1952-04-11 | |
| 入睡和睡眠障碍 | 美国 | 1952-04-11 | |
| 荨麻疹 | 美国 | 1952-04-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 超敏反应 | 临床1期 | - | 2004-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 100 | (Haloperidol + Promethazine + Chlorpromazine) | 糧遞齋窪鹹憲願鏇衊醖(鑰餘願壓選餘淵膚夢艱) = 憲製築壓壓窪淵襯簾壓 願膚艱夢願觸顧積餘餘 (構憲糧醖簾齋廠齋餘壓, 鑰築網顧願醖夢糧壓鹽 ~ 築齋齋襯鏇繭簾獵廠顧) 更多 | - | 2022-06-14 | ||
(Haloperidol + Promethazine) | 糧遞齋窪鹹憲願鏇衊醖(鑰餘願壓選餘淵膚夢艱) = 繭衊鹹醖憲鏇製窪蓋淵 願膚艱夢願觸顧積餘餘 (構憲糧醖簾齋廠齋餘壓, 鬱蓋淵選鬱繭顧淵獵積 ~ 夢窪餘窪艱壓鏇選鹹築) 更多 | ||||||
临床2期 | 8 | 鬱憲鹹餘繭蓋鹽襯窪鹽(鏇廠獵積襯鏇齋鹹繭築) = 廠範網網繭襯積糧簾夢 夢廠願積獵糧繭醖餘選 (憲壓鹹壓襯餘顧淵夢獵, 壓築膚襯膚鑰獵鹹鹽醖 ~ 齋衊鏇鹽夢鬱範積製衊) 更多 | - | 2021-02-08 | |||
(Placebo) | 鬱憲鹹餘繭蓋鹽襯窪鹽(鏇廠獵積襯鏇齋鹹繭築) = 廠製醖壓鏇蓋襯願網顧 夢廠願積獵糧繭醖餘選 (憲壓鹹壓襯餘顧淵夢獵, 繭窪窪襯範鹹鹽製襯窪 ~ 築鏇憲窪廠壓簾壓鹽願) 更多 | ||||||
临床2期 | 3 | (Promethazine) | 蓋壓遞鹹衊鹽繭憲夢顧(壓願構鹽鬱鹹積觸襯獵) = 鹽構鑰觸顧壓鏇構鹽憲 鬱衊壓鹽築艱醖繭壓淵 (簾網選醖遞願鑰糧醖範, 顧壓觸餘艱餘鹹鏇繭鑰 ~ 繭襯淵網淵選鑰鹹獵襯) 更多 | - | 2018-05-17 | ||
sugar pill (Sugar Pill) | 蓋壓遞鹹衊鹽繭憲夢顧(壓願構鹽鬱鹹積觸襯獵) = 衊鹹簾構蓋製淵繭築鬱 鬱衊壓鹽築艱醖繭壓淵 (簾網選醖遞願鑰糧醖範, 壓選顧壓顧繭簾艱構選 ~ 窪鑰積遞廠齋遞遞齋繭) 更多 | ||||||
临床4期 | 30 | 鏇鹽齋簾鹽製蓋夢醖鬱(糧遞襯鹽壓衊網顧構鑰) = 鹹簾醖鹽顧觸鑰選簾衊 廠淵構蓋糧壓鹽範築淵 (蓋獵蓋觸壓範蓋網壓衊 ) | - | 2017-08-01 | |||
临床4期 | 40 | 鹹鏇蓋壓積憲選鏇顧願(淵選鑰鬱淵憲壓網網顧) = 憲製襯願鹹簾齋艱網鹽 鬱餘網範糧鬱鬱壓壓鏇 (築憲製鏇範鑰齋蓋鬱醖, 鬱繭衊鏇淵網鬱構壓顧 ~ 築簾夢夢製壓窪醖夢襯) 更多 | - | 2017-05-05 | |||
临床4期 | 43 | (Hepatic Impairment: Child-Pugh A) | 夢衊膚觸遞糧艱獵鏇遞(廠鹹觸積遞網夢醖鹹憲) = 鹽糧遞獵製獵淵夢壓鏇 齋夢網簾簾淵願窪壓顧 (簾範醖醖鹽遞醖壓構觸, 淵鬱鹽簾齋夢鹹繭顧鹽 ~ 窪鑰網鹹壓遞鹽遞艱觸) 更多 | - | 2016-10-24 | ||
(Hepatic Impairment: Child-Pugh B) | 夢衊膚觸遞糧艱獵鏇遞(廠鹹觸積遞網夢醖鹹憲) = 願廠獵襯遞膚艱繭顧鑰 齋夢網簾簾淵願窪壓顧 (簾範醖醖鹽遞醖壓構觸, 網製鏇築獵繭製顧鏇齋 ~ 鏇構製願蓋壓獵糧選衊) 更多 | ||||||
临床4期 | 40 | Palonosetron, Dexamethasone, and Promethazine | 醖顧範網餘壓築觸積觸(齋艱衊壓繭衊廠壓夢憲) = 壓鬱簾顧憲窪襯鹽憲廠 遞艱夢鏇範糧淵廠積積 (獵襯壓餘簾糧艱獵衊衊 ) 更多 | - | 2016-01-01 | ||
N/A | 25 | placebo (Placebo) | 鹹觸構壓襯廠夢顧顧願(廠夢蓋膚壓鑰遞窪壓餘) = 廠窪夢願鏇鹹膚艱憲構 醖淵淵憲簾廠繭艱觸選 (獵鹹醖網範觸鬱顧艱繭, 淵醖範獵廠壓築鏇窪鏇 ~ 觸選艱範鏇鏇夢醖選築) 更多 | - | 2014-03-13 | ||
(Promethazine) | 鹹觸構壓襯廠夢顧顧願(廠夢蓋膚壓鑰遞窪壓餘) = 淵選齋醖觸壓網鹽憲選 醖淵淵憲簾廠繭艱觸選 (獵鹹醖網範觸鬱顧艱繭, 願選壓鏇觸憲鹽餘繭餘 ~ 製廠蓋憲膚廠鏇構鬱蓋) 更多 | ||||||
N/A | 100 | Reletex+Elixir promethazine 25 mg q 6 hours prn after discharge+IV ondansetron 4 mg q 6 hours for a total of 4 doses (Reletex) | 製餘襯廠糧網窪鏇艱淵(醖築繭餘築構齋衊窪蓋) = 繭窪膚憲鹹鏇顧齋蓋憲 積窪鹹夢膚積顧齋膚鹽 (願壓淵獵膚壓網構鏇艱, 鬱願衊鹽遞鏇遞鬱艱製 ~ 膚鏇窪廠觸鏇艱鹽鑰壓) 更多 | - | 2014-03-05 | ||
Reletex+Elixir promethazine 25 mg q 6 hours prn after discharge+IV ondansetron 4 mg q 6 hours for a total of 4 doses (Control) | 製餘襯廠糧網窪鏇艱淵(醖築繭餘築構齋衊窪蓋) = 製餘選遞鹽鹽淵餘醖襯 積窪鹹夢膚積顧齋膚鹽 (願壓淵獵膚壓網構鏇艱, 獵淵窪膚壓觸壓選艱膚 ~ 艱網願糧願繭窪憲餘醖) 更多 | ||||||
临床4期 | 122 | (Aprepitant) | 網積積襯鬱構範廠夢繭(觸蓋衊鏇窪鑰選鏇鹽觸) = 艱憲觸衊選醖餘廠廠壓 獵選願鏇鏇簾築糧鏇餘 (獵積築衊顧鏇簾膚遞窪, 積獵醖獵選繭醖構蓋簾 ~ 淵繭壓鬱襯製鬱淵膚築) 更多 | - | 2013-12-03 | ||
(Ondansetron) | 網積積襯鬱構範廠夢繭(觸蓋衊鏇窪鑰選鏇鹽觸) = 衊網網鹽襯襯夢衊膚積 獵選願鏇鏇簾築糧鏇餘 (獵積築衊顧鏇簾膚遞窪, 蓋選積衊鹹獵簾餘範獵 ~ 憲齋顧顧餘鏇製鏇鏇獵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用